Abbott and Exact Sciences have announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking ...

Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions ...

The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer ...

Madison-based Exact Sciences will be acquired by Abbott Laboratory for roughly $23 billion in a deal that was announced Nov.

Successful tech-based companies become so in different ways, a phenomenon on display of late with the announced $23 billion acquisition of Wisconsin’s Exact Sciences by Illinois-based Abbott ...

Exact Sciences, which bought Bay Area cancer testing pioneer Genomic Health in 2019, is projected to generate more than $3 ...

Abbott has signed a definitive agreement to acquire Exact Sciences’ all outstanding shares for an estimated enterprise value ...

You might also like Reliance Industries Halts Russian Crude Imports to Comply with EU Sanctions Paris Court Blocks Auction of Rare Pascal Calculator as Heritage Battle Intensifies U.S. Clears Massive ...

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or ...

Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...